[Click e-Stock] "WSI Expected to See Stock Revaluation with Obstetrics and Gynecology Assistant Robot"

Independent research firm Aris analyzed on July 11 that WSI is expected to see a stock price revaluation driven by its obstetrics and gynecology assistant robot, U-BOT. The firm did not provide an investment opinion or target price.

Lee Jaemo, a researcher at Aris, stated, "This year will be focused on preparing for the launch of U-BOT and targeting the global market," adding, "U-BOT is currently undergoing patent procedures in Europe and the United States, and exports are planned to expand from Korea to China, India, and other countries."

He continued, "The area that the market is most sensitively interested in is expected to be the robot business of the subsidiary EasyMedibot," and added, "Recently, listed company Koh Young has announced FDA approval and product supply timelines in the United States, signaling that cases of domestic surgical robots entering the US market are beginning to emerge. As a result, there is a possibility that stock price rerating for surgical robot companies may occur simultaneously."

He emphasized, "The timing of WSI's U-BOT commercialization and its moves to enter overseas markets could serve as triggers for stock price increases," and stated, "It is necessary to closely monitor product approvals and sales developments."